[Featured Stock] Andyforce Surges on News of Approval Process for COVID-19 and Flu Dual Diagnostic Kit
[Asia Economy Reporter Geum Bo-ryeong] AndyForce surged on the 8th following news that the government is in the process of approving certain kits that simultaneously diagnose COVID-19 and influenza viruses.
At 11:25 a.m. that day, AndyForce's stock price rose 12.12% (750 won) from the previous close to 6,940 won. During the session, it even soared to 7,630 won, setting a new 52-week high.
On the previous day, Jung Eun-kyung, head of the Central Disease Control Headquarters (CDCH), stated regarding the development of the COVID-19 and influenza simultaneous diagnostic kit, "I understand that several institutions are currently undergoing approval procedures with the Ministry of Food and Drug Safety."
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- Iranian Stock Market Reopens After 80 Days Following War
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
In July, AndyForce completed development of two molecular diagnostic kits that simultaneously diagnose COVID-19 and influenza: 'ND COVID-19 Flu' and the rapid diagnostic kit 'ND COVID-19 Flu Rapid kit.'
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
